Skip to main content
Clinical Trials/ISRCTN24452099
ISRCTN24452099
Recruiting
Not Applicable

Perspective study on an effective treatment for acute myeloid leukemia with decitabine and chemotherapy

Heilongjiang Institute for Hematology and Oncology Research (China)0 sites3,000 target enrollmentOctober 23, 2014

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Acute myeloid leukemia (AML)
Sponsor
Heilongjiang Institute for Hematology and Oncology Research (China)
Enrollment
3000
Status
Recruiting
Last Updated
10 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 23, 2014
End Date
TBD
Last Updated
10 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
Heilongjiang Institute for Hematology and Oncology Research (China)

Eligibility Criteria

Inclusion Criteria

  • 1\. Any age AML patients (except APL) at different treatment stages, who are responsive or non\-responsive to conventional treatments are all included in this trial
  • 2\. Patients agreed to receive the treatment

Exclusion Criteria

  • 1\. Previous history of severe cardiovascular disease (coronary arterial disease, stroke, etc.)
  • 2\. Severe chronic disease with poor prognosis (liver disease, kidney disease, etc.)
  • 3\. Illegal drug use or chronic alcoholism
  • 4\. Physical limitations, mental or intellectual disabilities
  • 5\. Any condition that may affect the development of this trial

Outcomes

Primary Outcomes

Not specified

Similar Trials